FindTrial
Sign In

effect of dhanvayasa in Diabetes type-2

Pharmacotherapeutic & Pharmacognostical Study Of Dhanvayasa (Fagonia cretica)in the Management Of Madhumeha (Diabetes Mellitus Type- 2) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078036
Enrollment
100
Registered
2024-12-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E08-E13- Diabetes mellitus

Interventions

None listed

Sponsors

Dr.Sarvepalli Radhakrishana Rajasthan Ayurved University Jodhpur
Lead Sponsor
DrRajendra Prasad Purvia
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosis and confirmed cases of Diabetes Mellitus type 2 on the bases of laboratory investigations. 2.FBS between 126 mg/dl to 200 mg/dl. 3.PPBS between 200 mg/dl to 300 mg/dl. 4.Glycated haemoglobin between 6.5% to 10% .

Exclusion criteria

Exclusion criteria: 1. Patients having type DM-1 2. Patients of DM-2 who are on the insulin therapy. 3. Diabetes Mellitus -2 With complications. 4. Uncontrolled DM. 5. Drug induced DM. 6. Malignant and accelerated HTN. 7. FBS below 126 mg/dl and above 200 mg/dl. 8. PPBS below 200 mg/dl and above 300 mg/dl. 9. DM with coronary artery disease. 10.Chronic DM. 11.Glycated haemoglobin below 6.5% to above 10%. 12.Pregnant woman and planning to be pregnant within six months.

Design outcomes

Primary

MeasureTime frame
Reduction in labortaory value of FBS,PPBS and Glycated haemoglobin in DM type-2 Patients.Timepoint: 3 months.—

Secondary

MeasureTime frame
To evaluate the effect of Dhanvayasa (Fagonia cretica) on DM Type -2.Timepoint: 2 months—

Countries

India

Contacts

Public ContactDr Jaya Kachchhwaha

PGIA,DSRRAU,jodhpur

drrajpurvia@gmail.com9782230577

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026